For more information on the event and to pre-register please visit www.cphi.com/europe/
To attend CPhI worldwide 2018, pre-register now.
We are looking forward to meet you at our booth!
Biomess, with its headquarters located in Mönchengladbach, is one of the leading providers of laboratory analysis and consulting services concerning asbestos and mold. Additionally, they provide services such as hygienic inspections of ventilation and air-conditioning systems, as well as drinking water analysis. Their customers include construction companies, engineering firms, public agencies, and an increasing amount of small companies of skilled craftsmen.
Dr. Dominik Obeloer, Managing Director of biomess, says: “By making use of the GBA Group’s vast network, we are significantly increasing the availability of our services in the German-speaking region. This enables us to provide our core services to additional customers in new regions.” Ralf Murzen, Managing Director of the Environmental Division of the GBA Group adds: “By combining the competencies of both companies, GBA closes an important gap that we had in our portfolio, specifically, issues concerning contaminants within buildings. Due to their strong focus on fast and reliable customer service, biomess is an ideal fit with GBA. We are pleased to welcome our new colleagues to the GBA Group!” Dr. Alexander Friedrich, Partner at Quadriga Capital Eigenkapitalberatung GmbH, commented: “The addition of biomess to the GBA Group represents a very important strategic milestone in the completion of the value chain in the environmental sector. The advisory board and the investors of the GBA Group welcome the managers and employees of biomess to the GBA Group.”
About the GBA Group
The GBA Group, founded in 1989, brings together a network of dynamic companies providing laboratory analysis and related services to customers in three major sectors: food, environment, and pharmaceuticals. Each of our divisions is known on the market for providing customized solutions that meet the needs of our customers. At the GBA Group, our expert employees maintain a strong focus on providing high-quality service by communicating with our customers intensively.
Please direct any further questions to:
Ms. Sabine Nest
By taking this step, the GBA Group strengthens its market position in Austria, expands its international laboratory network to 18 locations, and lays the foundation for expanding its business activities into southeast Europe.
Hygienicum, founded in Graz in 1994, is one of the leading laboratories and providers of consulting services for the food industry and trade in Austria. With around 80 employees, its domestic and international customers know that Hygienicum stands for high quality services in laboratory analysis, R&D support, as well as consulting in the field of industrial hygiene and marketability.
Mark Piekereit, Co-CEO of the GBA Group Food Division says: “With the merger of Hygienicum and the GBA Group, both companies can expand their service portfolios, expertise, and their access to state-of-the-art laboratory facilities. Moving forward together, this offers us the potential to provide our customers with even more comprehensive support.” Dr. Michael Stelzl, Hygienicum Managing Director and shareholder, adds: “Having the GBA Group by our side opens up exciting opportunities for us now to expand together even further into neighboring markets.” Dr. Stelzl will retain his function as Managing Director and significant partner of Hygienicum. Dr. Alexander Friedrich, partner of Quadriga Capital Eigenkapitalberatung GmbH, explains the dynamic development of the GBA Group: “With Hygienicum joining the GBA Group, this is now the seventh time since 2016 that an innovative and fast-growing company, along its management, has become part of the GBA family. This once again solidifies the appeal of GBA – which is propelled forward every day by the actions of all GBA employees – as a trusted partner with a unique symbiosis of institutionalized processes, strong entrepreneurial management, and a shared drive for success.”
The transaction is still pending the approval of the responsible government authorities.
About the GBA Group
The GBA Group, founded in 1989, unites a network of dynamic companies in the field of laboratory analysis and related services for customers in the food industry, environmental field, and pharmaceutical sector. Each division is known in its market sector for individualized solutions that fulfill the needs of the customers. The company’s strong focus on providing high quality service is carried out by skilled employees in close communication with our customers.
Please address any questions to:
Ms. Sabine Nest
At the GBA Laboratory Group, we are committed to handling your data confidentially. With the GDPR in effect, there is an even higher degree of sensitivity when dealing with personal data. Processes that involve personal data are therefore handled with the appropriate level of care and diligence. We utilize your data only for fulfilling the terms of the contract or executing your order as agreed upon. We do not forward your data to third parties for advertising or similar purposes.
We have updated and adapted our Terms & Conditions as well as our Data Privacy Statement in the context of the GDPR.
Further information about data protection at the GBA Laboratory Group can be found at: https://www.gba-group.de/en/data-privacy/
Since LKF GmbH was founded, it has been involved in more than 1,800 international clinical studies as the central laboratory in phases I-IV. The company has a wide range of activities, including reporting consultation, training seminars, documentation, kit preparation, laboratory analysis, logistics, storage, data transfer, and archiving samples and documents. With over 100 employees and strong global business partners, LKF is an internationally recognized central laboratory that meets the high quality standards and logistical demands of the international pharmaceutical and biotech industry.
After the merger, the GBA Laboratory Group will be able to offer a special combination of services in the field of clinical trial material supply and central laboratory activities that is unique in the European Union. Moreover, the GBA Laboratory Group’s international network, for example in regions such as China, will be expanded even further.
Dr. Elisabeth Lackner, Managing Director of the GBA Pharma Division has stated: “With the unparalleled combination of expertise in the fields of manufacturing clinical supplies and central laboratory services, we now can finally satisfy a customer demand that has been repeatedly expressed. We are looking forward to the cooperation and will further strengthen the location in Kiel.”
Bärbel Wilke, Managing Director of LKF GmbH says: “The expanded range of services that we can offer together, along with a shared market presence, opens up the potential for LKF to develop sustainably while entering new fields of business and markets.”
The GBA Gesellschaft für Bioanalytik mbH and the GBA Pharma Division, together under the name GBA Laboratory Group, are among the leading analytical laboratories and service providers in Europe, with their highly specialized divisions for food, environmental, and pharmaceutical analysis. The GBA Pharma Division possesses extensive experience in dealing with small molecules as well as larger molecules, biological and cell-based therapies, and supports projects in the field of drug discovery, from pre-clinical studies to clinical studies, with our production and logistics of clinical testing goods and central laboratory services, as well as providing analyses in the later phases of pharmaceutical development, including QP batch release.
If you have any questions, please contact:
GBA Laboratory Group
Ms. Sabine Nest